RIPK2 inhibitors and method of treating cancer with same

A compound represented by Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• Cy is cycloaliphatic, heterocyclyl, aryl, or heteroaryl;
• Y is absent, —CRbRb—, —O—, —NRb—, —S(O)n—;
• R1 is cycloaliphatic, heterocyclyl, aryl or heteroaryl, each of which is optionally substituted with 1 to 3 groups individually represented by Ra;
• R3 is H, heterocyclyl or heteroaryl optionally substituted with 1 to 3 groups selected from —F, —Cl, —Br, I, —CN, —NO2, —ORb, —C1-C4alkyl, —(C1-C3)alkylene-ORb, —(C1-C3)alkylene-NRbRb, —C1-C4haloalkyl, —C1-C4haloalkoxy, (C3-C8)cycloalkyl, —NRbRb, —C(═O)NRbRb, —NRb(C═O)NRbRb, —S(O)nNRbRb, C(═O)ORb, —OC(═O)ORb, —S(O)nRb, —NRbS(O)nRb, —C(═S)ORb, —O(C═S)Rb, —NRbC(═O)Rb, —C(═S)NRbRb, —NRbC(═S)Rb, —NRb(C═O)ORb, —O(C═O)NRbRb, —NRb(C═S)ORb, —O(C═S)NRbRb, NRb(C═S)NRbRb, —C(═S)Rb or —C(═O)Rb;
• each R4 is independently selected from —F, —Cl, —Br, I, —CN, —NRbRb, —ORb, —C1-C4alkyl, —(C1-C3)alkylene-ORb, —(C1-C3)alkylene-NRbRb, —C1-C4haloalkyl, or —C1-C4haloalkoxy;
• each Ra is independently selected from —F, —Cl, —Br, I, —CN, ORb, —C1-C4alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, —C1-C4haloalkyl, —C1-C4haloalkoxy, —(C1-C3)alkylene-ORb, or —(C1-C3)alkylene-NRbRb;
• each Rb is independently —H or —C1-C4alkyl;
• x is 0, 1, 2, 3, or 4;
• each m is independently 0, 1, 2, or 3;
• and
• each n is independently 0, 1, or 2.